Why Aren't Specialty Pharmacy Drugs Available at Walgreens in 2026?

Specialty pharmacy drugs are a category of high-cost, complex medications, mostly biologics, that the FDA and insurers treat differently from ordinary generic or brand pills. The Medicare Part D specialty tier includes any drug with a monthly cost above roughly $950 in 2026, and most drugs on that tier require refrigerated cold-chain shipping, specialized handling, or ongoing safety monitoring under an FDA Risk Evaluation and Mitigation Strategy (REMS) program. Humira (adalimumab), Enbrel (etanercept), Stelara (ustekinumab), Skyrizi (risankizumab), Dupixent (dupilumab), and Repatha (evolocumab) are six of the most commonly prescribed examples, covering rheumatoid arthritis, psoriasis, Crohn's disease, atopic dermatitis, and high cholesterol.

Manufacturers sign exclusive or limited distribution agreements with a short list of certified specialty pharmacies rather than shipping product to every retail chain. Accredo (Express Scripts/Cigna), CVS Specialty, OptumRx SpecialtyRx, and Walgreens Specialty Pharmacy (branded separately as AllianceRx Walgreens Prime in some markets) account for most of the volume. A patient's own insurer or pharmacy benefit manager (PBM) often mandates one specific specialty pharmacy in the plan's network, which is why two people with the same prescription and different insurance may be told to use two completely different mail-order pharmacies. Retail counters at Walmart, Costco, and most Kroger locations simply are not part of these networks for the highest-cost biologics, even though the parent chains may operate a separate specialty pharmacy division.

Cost varies enormously across this drug category, from about $620 a month for Repatha to more than $20,000 a month for Skyrizi, based on 2026 wholesale acquisition cost (WAC) data. Two of the drugs in this guide, Enbrel and Stelara, are among the first 10 drugs selected for Medicare price negotiation under the Inflation Reduction Act, with Maximum Fair Prices taking effect January 1, 2026. Patients prescribed Humira should also compare the growing biosimilar market before assuming brand pricing applies, and readers researching a specific biologic should check that drug's dedicated page, such as Humira cost, Stelara cost, or Enbrel cost, for exact 2026 figures.

What Specialty Pharmacy Drugs Costs by Point of Pay (2026)

The price you pay depends almost entirely on WHERE you pay. The same specialty pharmacy drugs can cost many times more at a hospital than at your local pharmacy:

Why Hospitals Charge So Much

Hospitals and infusion centers bill specialty biologics differently depending on who buys the drug. Under the traditional buy-and-bill model, the clinic purchases the vial directly from a wholesaler and bills Medicare Part B or commercial insurance for both the drug and the administration. Under white bagging, the patient's specialty pharmacy ships the pre-filled dose directly to the clinic, and the facility only bills for administering it. Under brown bagging, the patient personally picks up the drug from the specialty pharmacy and carries it to the appointment. Each model shifts where the markup lands, and insurers increasingly require white bagging specifically to prevent the buy-and-bill markup.

Facility markups on buy-and-bill infused biologics can run several times the specialty pharmacy cash price, sometimes reaching $60,000 or more per infusion for the highest-cost oncology and immunology drugs. Patients who see a specialty biologic on an itemized inpatient or outpatient infusion-center bill should request the National Drug Code (NDC) and compare it against the drug's published wholesale acquisition cost. Charges more than three times the WAC are a common and often successful appeal target, especially when the insurer's plan documents specify a preferred white-bagging arrangement that the facility bypassed.

Patient Assistance Programs

Manufacturers of specialty biologics run some of the most generous patient assistance programs in the pharmaceutical industry because the cash price without insurance is so high. An uninsured patient facing a $620 to $24,000 monthly bill can often receive the drug entirely free through the manufacturer's foundation-run PAP, a dramatically different outcome than paying retail. Each of the six brands in this guide has its own program with its own income cutoff and application portal.

Medicare Part D

Medicare Part D places nearly every specialty biologic on its highest formulary tier, called the specialty tier, reserved in 2026 for drugs costing more than roughly $950 per month. For 2026, total out-of-pocket spending across all Part D drugs combined is capped at $2,100 under the Inflation Reduction Act, so once a patient reaches that cap, every covered drug, including a specialty biologic, is $0 for the rest of the calendar year.

Enbrel and Stelara receive an additional layer of protection because they carry a Medicare-negotiated Maximum Fair Price effective January 1, 2026. That negotiated price, not the manufacturer's list price, sets the baseline that Part D plans and patients pay before the $2,100 cap applies. Prior authorization and step therapy remain standard for nearly every specialty biologic under Part D, and the plan will only cover the drug through its designated network specialty pharmacy.

Medicare's Prescription Payment Plan, available starting in 2025, lets Part D enrollees spread their annual out-of-pocket costs evenly across monthly installments instead of paying a large bill in the first fill of the year. Patients newly prescribed a $4,000 or $10,000 specialty drug should ask their Part D plan about this option to avoid a single large upfront charge.

Common Specialty Pharmacy Drugs Billing Errors

Specialty pharmacy billing has more failure points than a standard retail prescription. Watch for these issues before paying a bill above the ranges listed in this guide:

• Buy-and-bill charge appearing on a facility bill when the plan's contract required white bagging through the designated specialty pharmacy instead. This can add thousands of dollars in facility markup.
• Prior authorization expired or never renewed. Most specialty biologics require annual PA renewal, and a lapsed authorization causes the specialty pharmacy to bill full cash price on the next refill.
• Copay accumulator or maximizer program preventing a manufacturer copay card from counting toward the deductible, leaving the patient owing the full deductible even though the card paid the pharmacy.
• Wrong specialty pharmacy used for the fill, triggering an out-of-network denial even though the drug itself is on formulary. Always confirm the plan's mandated specialty pharmacy before the first fill.
• Manufacturer PAP-supplied drug billed to the patient's insurance anyway, resulting in a coordination-of-benefits error and a surprise bill for a drug that should have been free.
• Infused dose charged at the buy-and-bill facility rate of $10,000 or more when the same biosimilar dose is available through the specialty pharmacy channel for a fraction of the cost.

Frequently Asked Questions